United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

17 Feb 2017
Change (% chg)

$-0.00 (-0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Wasman, Jane 

Ms. Jane Wasman, J.D., is President - International, General Counsel, Corporate Secretary of Acorda Therapeutics, Inc. Prior to that, from January 2012 until October 2012, she was our Chief, Strategic Development, General Counsel and Corporate Secretary; and from May 2004 until January 2012, she was our Executive Vice President, General Counsel and Corporate Secretary. From 1995 to 2004, she held various leadership positions at Schering-Plough Corporation, including Staff Vice President and Associate General Counsel responsible for legal support for U.S. Pharmaceuticals operations, including sales, marketing and compliance; FDA regulatory matters; and global research and development. She served as Staff Vice President, International in 2001 and as Staff Vice President, European Operations-Legal from 1998 to 2000. Previously, Ms. Wasman specialized in litigation at Fried, Frank, Harris, Shriver & Jacobson. She also served as Associate Counsel to the U.S. Senate Committee on Veteran’s Affairs. Ms. Wasman graduated Magna Cum Laude and Phi Beta Kappa from Princeton University and earned her J.D. from Harvard Law School. Ms. Wasman is a member of the board of directors and the executive committee of the board of the New York Biotechnology Association (NYBA).

Basic Compensation

Total Annual Compensation, USD 910,164
Restricted Stock Awards, USD 324,885
Long-Term Incentive Plans, USD --
All Other, USD 1,099,230
Fiscal Year Total, USD 2,334,280

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 44,769 1,185,360.00
Name Fiscal Year Total

Ron Cohen


David Lawrence


Andrew Blight


Jane Wasman


Burkhard Blank


Andrew Hindman

As Of  30 Dec 2014